Researchers at LSTM and Imperial College London have designed drugs which could help combat any potential new flu pandemic, by targeting the receptors of the cells by which the virus gains entry to the human body.
In a paper published today(link is external) in the Journal of Immunology the team, led by LSTM’s Professor Richard Pleass, show that by engineering a part of an antibody they can target the viral proteins that allow flu to mutate and become so deadly to humans.
Last year marked the centenary of the 1918 influenza pandemic that claimed nearly 100 million lives worldwide, thus becoming the deadliest disease outbreak in recorded history. Global annual influenza outbreaks account for 300,000-650,000 respiratory deaths, mostly in children and the elderly.
Professor Pleass explained: “Influenza vaccines have limited public health impact during pandemics, and current influenza vaccines are less efficacious than vaccines for many other infectious diseases. This is because influenza viruses that circulate in human and animal populations mutate two key viral surface proteins, haemagglutinin (HA) and neuraminidase (NA), thus allowing them to escape from protective antibodies produced through natural infection or vaccination”
Both HA and NA target a sugar called sialic acid, that is found in abundance on the receptors of cells lining the mammalian respiratory tract, which the virus uses to gain entry into the body. The sialic acid-binding contacts on HA and NA do not mutate readily, otherwise the virus would not be able to infect human cells.
The team has engineered antibody Fc fragments with enhanced sialic acid that target these conserved parts of both HA and NA, binding influenza viruses and thus blocking their interactions with human cells.
By targeting sialic acid, these engineered biologicals may also be useful in the control of other pathogens, such as group B streptococci, Streptococcus pneumoniae, Mycoplasma genitalium, and Newcastle Disease Virus.
“Better anti-influenza therapeutics are urgently needed.” Continued Professor Pleass: “The transfer of antibodies from people recovering from influenza during the 1918 and 2009 pandemics reduced mortality from influenza by 50% and 26% respectively. However, to be useful, these antibody medicines (also called FLU-IVIG) need to be manufactured in advance of future epidemics, which is obviously problematic as there may be modest or little neutralising activity against newly emerging strains. Therefore, combinations of existing medicines, including FLU-IVIG, with sialic acid blockers could increase their efficacy while future-proofing against the next pandemic.”
Professor Sara Marshall, Head of Clinical and Physiological Sciences at the Wellcome Trust, who provided funding for this work, said: “This is a fascinating project, and one which could have really far-reaching impact not only for influenza but as a platform technology to develop new medicines for many other diseases that are currently treated by antibodies.”
The technology described is available for licensing.
The Latest on: Anti-influenza drugs
via Google News
The Latest on: Anti-influenza drugs
- Emory researchers to use $15 million NIAID contract to fight influenzaon October 23, 2019 at 12:09 pm
A $15.89 million National Institute of Allergy and Infectious Disease (NIAID) contract gives the university’s concerted efforts to fight influenza a major shot in the arm by enabling researchers to ...
- Snapshots of the flu virus replication machine in actionon June 4, 2019 at 5:32 am
These results, published in Nature Structural & Molecular Biology, provide valuable information for the next generation of anti-influenza drugs. "Studying and understanding the unique mechanisms ...
- New Anti-influenza Drugs Designedon January 28, 2019 at 5:01 pm
Drugs which could combat flu pandemic ... and Newcastle Disease Virus. "Better anti-influenza therapeutics are urgently needed." Continued Professor Pleass: "The transfer of antibodies from ...
- Researchers design new anti-influenza drugson January 25, 2019 at 1:19 pm
Researchers at LSTM and Imperial College London have designed drugs which could help combat ... and Newcastle Disease Virus. "Better anti-influenza therapeutics are urgently needed." ...
- FUJIFILM Corporation signs MoU on clinical development of anti-influenza virus drug in Chinaon October 29, 2018 at 2:00 am
This clinical development seeks to develop a therapy for the treatment of serious influenza patients using the active ingredient of Avigan tablets, which have already acquired Japan's manufacturing ...
- New research will guide development of new anti-influenza drugson March 14, 2016 at 12:06 pm
chair of the St. Jude Department of Structural Biology. Developing new anti-influenza drugs is critical because they are the only weapons that can initially battle an outbreak of new flu strains.
- St. Jude research will guide development of new anti-influenza drugson March 14, 2016 at 12:03 pm
Developing new anti-influenza drugs is critical because they are the only weapons that can initially battle an outbreak of new flu strains. "It may take six months or more from identifying a new ...
- Research will guide development of new anti-influenza drugson March 13, 2016 at 5:00 pm
Research will guide development of new anti-influenza drugs Date: March 14, 2016 Source: St. Jude Children's Research Hospital Summary: Scientists have revealed new details about how a promising ...
- NanoViricides, Inc. Reports Excellent Safety Profile of Its Broad-Spectrum anti-Influenza Drug Candidate, FluCide(TM) , in a Non-GLP Studyon December 1, 2013 at 11:00 pm
No overt adverse safety and toxicology effects were observed in this study of the Company's optimized FluCide broad-spectrum anti-influenza drug candidate, even at the maximum feasible dose level.
- Harnessing anticancer drugs for the future fight against influenzaon September 5, 2012 at 8:46 am
They also identified two novel anti-influenza agents ... yliopisto (University of Helsinki). "Harnessing anticancer drugs for the future fight against influenza." ScienceDaily.
via Bing News